News

The median progression-free survival was not reached with selpercatinib vs 16.8 months with other kinase inhibitors.

Adjuvant alectinib significantly improved disease-free survival in patients with ALK-positive, early-stage, non–small-cell lung cancer.

Treatment with neoadjuvant nivolumab, followed by adjuvant nivolumab after surgery, led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.

The FDA has approved entrectinib to treat pediatric patients ages 1 month and older with NTRK-positive solid tumors.

The Health Resources and Services Administration has announced that it will be investing in the training of new nurses and growing the workforce.

Tarlatamab induced a 40% objective response rate among patients with pretreated small cell lung cancer—including many patients who had already received 3 lines of therapy.

The FDA has approved tests to identify patients with metastatic non–small cell lung cancer who are eligible for treatment with encorafenib plus binimetinib.

The FDA has granted priority view to osimertinib plus chemotherapy based on data from the phase 3 FLAURA2 trial.

The FDA has approved pembrolizumab with platinum-containing chemotherapy for patients with resectable non–small cell lung cancer, in both the neoadjuvant and adjuvant setting.

An analysis of 3 randomized trials showed that acalabrutinib was associated with approximately half the number of cardiac toxicities than with comparator treatments.

Fixed-duration venetoclax plus rituximab continued to outperform bendamustine plus rituximab in the phase 3 MURANO trial.

Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.

Clinical navigators helped increase the rate of genomic testing referrals among Black patients with prostate cancer—a group that faces significant health disparities in the care system.

Kim Noonan, DNP, ANP-BC, AOCN, FAAN, discusses how nurses can help patients with myeloproliferative neoplasms prevent cardiovascular and thrombotic events.

Liquid biopsies helped determine which patients with cervical cancer were at a high risk of recurrence following chemoradiation.

The FDA has approved encorafenib plus binimetinib to treat adults with metastatic non-small cell lung cancer with a BRAF V600E mutation.

The approval of FoundationOne CDx as a companion diagnostic for selpercatinib seeks to broaden access to therapies for patients with RET fusion–positive solid tumors.

Nivolumab plus chemotherapy offers patients with gastric and esophageal cancers a reduced risk of symptom burden and a longer time to deterioration.

Hyperthermic intraperitoneal chemotherapy, also known as hot chemotherapy bath, showed a long-term overall survival improvement in patients with stage III primary epithelial ovarian cancer.

Noël Arring, PhD, DNP, RN, and Debra L. Barton, PhD, RN, FAAN, FASCO, discuss clinical strategies to address sexual dysfunction in female cancer survivors.

Chemotherapy shortages are affecting patients across the country.

Takeda has announced that they will be voluntarily withdrawing mobocertinib for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

The FDA Oncologic Drugs Advisory Committee voted 10-to-2 that findings from the phase 3 CodeBreaK 200 trial cannot be reliably interpreted.

Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.

Sarita M. Taylor, BSN, RN, OCN, shares how she mentally recharges outside of the clinic.

Using diagnostic CT scans to create palliation plans may save time and improve the patient experience.

The FDA has granted marketing authorization to the Invitae Common Hereditary Cancers Panel, which can detect multiple genetic variants associated with hereditary cancers.

Patients with early breast cancer may safely choose a shorter course of radiation therapy following reconstruction.

Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma.

Resistance training and walking can be beneficial for patients with multiple myeloma.